Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy
GV Kondagunta, J Sheinfeld, M Mazumdar… - Journal of clinical …, 2004 - ascopubs.org
GV Kondagunta, J Sheinfeld, M Mazumdar, TV Mariani, D Bajorin, J Bacik, GJ Bosl…
Journal of clinical oncology, 2004•ascopubs.orgPurpose To assess the long-term relapse-free survival and overall survival of patients with
stage II nonseminomatous germ cell tumor (NSGCT) who received two cycles of adjuvant
etoposide and cisplatin (EP) after primary retroperitoneal lymph node dissection. Patients
and Methods Eighty-seven patients with completely resected pathologic stage II NSGCT
were treated with adjuvant EP chemotherapy. Adjuvant EP consisted of two cycles of
etoposide (100 mg/m2) plus cisplatin (20 mg/m2) per day, administered days 1 to 5 at a 21 …
stage II nonseminomatous germ cell tumor (NSGCT) who received two cycles of adjuvant
etoposide and cisplatin (EP) after primary retroperitoneal lymph node dissection. Patients
and Methods Eighty-seven patients with completely resected pathologic stage II NSGCT
were treated with adjuvant EP chemotherapy. Adjuvant EP consisted of two cycles of
etoposide (100 mg/m2) plus cisplatin (20 mg/m2) per day, administered days 1 to 5 at a 21 …
Purpose
To assess the long-term relapse-free survival and overall survival of patients with stage II nonseminomatous germ cell tumor (NSGCT) who received two cycles of adjuvant etoposide and cisplatin (EP) after primary retroperitoneal lymph node dissection.
Patients and Methods
Eighty-seven patients with completely resected pathologic stage II NSGCT were treated with adjuvant EP chemotherapy. Adjuvant EP consisted of two cycles of etoposide (100 mg/m2) plus cisplatin (20 mg/m2) per day, administered days 1 to 5 at a 21-day interval.
Results
Ten patients (11%) had pN1 disease, 73 (84%) had pN2 disease, and four (5%) had pN3 disease. Eighty-six patients received two cycles of EP, and one patient received an additional two cycles of EP after a transient marker increase after his first cycle. Eighty-seven patients are alive, and 86 patients (99%) remain relapse-free at a median follow-up of 8 years (range, 0.9 to 13.5 years).
Conclusion
Two cycles of adjuvant EP is highly effective in preventing relapse in patients with pathologic stage II pN1 and pN2 NSGCT. An alternative treatment strategy is surveillance with full-course chemotherapy at relapse. Because there is a higher risk of relapse for patients with pN2 disease, these patients are offered adjuvant chemotherapy.
ASCO Publications